Cargando…

Theory Meets Practice for Immune Checkpoint Blockade in Small-Cell Lung Cancer

Detalles Bibliográficos
Autores principales:	Riess, Jonathan W., Lara, Primo N., Gandara, David R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Clinical Oncology 2016
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477925/ https://www.ncbi.nlm.nih.gov/pubmed/27601544 http://dx.doi.org/10.1200/JCO.2016.69.0040

Ejemplares similares

Corticosteroids and immune checkpoint blockade
por: Min, Le, et al.
Publicado: (2015)

Combination of phototherapy with immune checkpoint blockade: Theory and practice in cancer
por: Zhao, Yujie, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in the Pre-operative Setting and Impact on the Primary Renal Tumor
por: Gulati, Shuchi, et al.
Publicado: (2022)

The Emerging Role of NK Cells in Immune Checkpoint Blockade
por: Martinez-Perez, Alejandra, et al.
Publicado: (2022)

Systemic immunological biomarkers of clinical responses in immune checkpoint blockade therapies
por: Arasanz, Hugo, et al.
Publicado: (2018)

Cancer Mutational Load: The More the Merrier for Immune Checkpoint Blockade Therapies
Publicado: (2016)

LIGHTing tumor up for checkpoint blockade
por: Liang, Yong, et al.
Publicado: (2016)

Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel?
por: Paglialunga, Luca, et al.
Publicado: (2016)

Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer
por: Liu, Xiaoming, et al.
Publicado: (2017)

Immune checkpoint blockade and biomarkers of clinical response in non–small cell lung cancer
por: Hallqvist, Andreas, et al.
Publicado: (2020)

Immune checkpoint inhibitors and the shared epitope theory: from hypothesis to practice
por: Lerrer, Shalom, et al.
Publicado: (2019)

Inhibiting the inhibitors: Checkpoints blockade in solid tumors
por: Mavilio, Domenico, et al.
Publicado: (2013)

TTF-1 and immune checkpoint therapy in non-small cell lung cancer
por: Gumbleton, Matthew, et al.
Publicado: (2023)

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
por: Hastings, K, et al.
Publicado: (2019)

Immune checkpoint blockade in HIV
por: Gubser, Celine, et al.
Publicado: (2022)

CD47: The Next Frontier in Immune Checkpoint Blockade for Non-Small Cell Lung Cancer
por: Lau, Asa P. Y., et al.
Publicado: (2023)

Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non–Small-Cell Lung Cancer
por: McCoach, Caroline E., et al.
Publicado: (2021)

Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer
por: Ravi, Arvind, et al.
Publicado: (2023)

Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients
por: Pabla, Sarabjot, et al.
Publicado: (2019)

Re-administration of immune checkpoint inhibitors for patients with non-small cell lung cancer
por: Hakozaki, Taiki
Publicado: (2022)

Immune checkpoint inhibitors for patients with gene-rearranged non-small cell lung cancer
por: Uehara, Yuji, et al.
Publicado: (2022)

Perspective: cancer vaccines in the era of immune checkpoint blockade
por: Cebon, Jonathan
Publicado: (2018)

Generalization and representativeness of phase III immune checkpoint blockade trials in non‐small cell lung cancer
por: Yoo, Shin Hye, et al.
Publicado: (2018)

The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer
por: Ren, Sijia, et al.
Publicado: (2021)

Immune Checkpoint Blockade Enhances Immune Activity of Therapeutic Lung Cancer Vaccine
por: Kadam, Pournima, et al.
Publicado: (2020)

Heating it up: Oncolytic viruses make tumors ‘hot’ and suitable for checkpoint blockade immunotherapies
por: Gujar, Shashi, et al.
Publicado: (2018)

Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade
por: Harel, Michal, et al.
Publicado: (2022)

Immune checkpoint blockade in ovarian cancer
por: Weiss, Lukas, et al.
Publicado: (2016)

Hallmarks of response to immune checkpoint blockade
por: Cogdill, Alexandria P, et al.
Publicado: (2017)

Immune-Checkpoint Blockade Therapy in Lymphoma
por: Kuzume, Ayumi, et al.
Publicado: (2020)

Activation of phagocytosis by immune checkpoint blockade
por: Li, Chia-Wei, et al.
Publicado: (2018)

Neutrophils in the era of immune checkpoint blockade
por: Faget, Julien, et al.
Publicado: (2021)

Curing glioblastoma: oncolytic HSV-IL12 and checkpoint blockade
por: Saha, Dipongkor, et al.
Publicado: (2017)

MCT4 blockade increases the efficacy of immune checkpoint blockade
por: Babl, Nathalie, et al.
Publicado: (2023)

Rethinking immune checkpoint blockade: ‘Beyond the T cell’
por: Liu, Xiuting, et al.
Publicado: (2021)

Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer
por: Tian, Yaru, et al.
Publicado: (2019)

CD66b as a prognostic and predictive biomarker in patients with non-small cell lung cancer treated with checkpoint blockade immunotherapy
por: Jain, Swati, et al.
Publicado: (2023)

Immune checkpoint inhibitors and driver oncogenes in non-small cell lung cancer
por: Miura, Yosuke, et al.
Publicado: (2019)

Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer
por: Zielinski, C., et al.
Publicado: (2013)

PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancer
por: Zhou, Huaqiang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_40p3c669lgs0n4punl9fvpa39j